RSV Seasonal Vaccine Introduction and Growth Strategy slide image

RSV Seasonal Vaccine Introduction and Growth Strategy

Upcoming pipeline catalysts: 2023 and 2024 Regulatory submission & acceptance Regulatory decision Phase II Late stage readouts Phase III H2 2023 H12024 H2 2024 Infectious diseases HIV (VIIV) Respiratory/Immunology Oncology Opportunity driven Jemperli - RUBY, DMMR/MSI-H IL endometrial cancer momelotinib - MOMENTUM, myelofibrosis cabotegravir (long-acting) pre-exposure Vocabria HIV treatment RSV older adults vaccine candidate - ā‰„60 YoA US EU CN JP 55 US Jemperli - RUBY, DMMR/MSI-H 1L endometrial cancer momelotinib - MOMENTUM, myelofibrosis EU Nucala severe asthma CN EU, JP ā€• Nucala CRSWNP gepotidacin - EAGLE-2/3, UUTI Arexvy 50-59 YOA JP US, EU US, EU, JP Nucala CRSWNP momelotinib - MOMENTUM, myelofibrosis gepotidacin - EAGLE-2/3, UUTI Arexvy -50-59 YoA CN, JP JP US, EU US, EU, JP Blenrep - DREAMM-7, 2L+ multiple myeloma Blenrep - DREAMM-8, 2L+ multiple myeloma Jemperli - RUBY part 2, IL endometrial cancer MenABCWY vaccine 1st Gen US, EU Nucala MATINEE, COPD US, EU gepotidacin- - EAGLE-1, GC US, EU US, EU - Blenrep DREAMM-7, 2L+ multiple myeloma Blenrep - DREAMM-8, 2L+ multiple myeloma Arexvy 50-59 YoA Jemperli - RUBY part 2, IL endometrial cancer Zejula - FIRST, IL maintenance ovarian cancer gepotidacin - EAGLE-1, GC linerixibat - GLISTEN, cholestatic pruritus in PBC depemokimab - SWIFT-1/2, asthma depemokimab - ANCHOR-1/2, CRSWNP Nucala - MATINEE, COPD cobolimab - COSTAR, 2L NSCLC Zejula' - ZEAL, IL maintenance NSCLC GSK 1. Tesaro asset bepirovirsen B-TOGETHER, HBV MenABCWY vaccine 2nd Gen 36 36 US US 553
View entire presentation